• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Virol Rapid Implementation and Validation of a Cold-Chain Free SARS-CoV-2 Diagnostic Testing Workflow to Support Surge Capacity

tetano

Editor, Senior Moderator
J Clin Virol


. 2020 May 23;128:104469.
doi: 10.1016/j.jcv.2020.104469. Online ahead of print.
Rapid Implementation and Validation of a Cold-Chain Free SARS-CoV-2 Diagnostic Testing Workflow to Support Surge Capacity


Andrew Bosworth[SUP] 1 [/SUP], Celina Whalley[SUP] 2 [/SUP], Charlie Poxon[SUP] 3 [/SUP], Kasun Wanigasooriya[SUP] 2 [/SUP], Oliver Pickles[SUP] 2 [/SUP], Erin L Aldera[SUP] 4 [/SUP], Danai Papakonstantinou[SUP] 4 [/SUP], Gabriella L Morley[SUP] 4 [/SUP], Eloise M Walker[SUP] 4 [/SUP], Agnieszka E Zielinska[SUP] 4 [/SUP], Dee McLoughlin[SUP] 4 [/SUP], Craig Webster[SUP] 5 [/SUP], Tim Plant[SUP] 6 [/SUP], Andrew Ellis[SUP] 6 [/SUP], Alex Richter[SUP] 6 [/SUP], I Michael Kidd[SUP] 1 [/SUP], Andrew D Beggs[SUP] 7 [/SUP]



Affiliations
Free PMC article

Abstract

Background: In January 2020 reports of unidentified severe respiratory illness were described in Wuhan, China. A rapid expansion in cases affecting most countries around the globe led to major changes in the way people live their daily lives. In the United Kingdom, the Department of Health and Social Care directed healthcare providers to establish additional resources to manage the anticipated surge in cases that could overwhelm the health services. A priority area was testing for SARS-CoV-2 RNA and its detection by qualitative RT-PCR.
Design: A laboratory workflow twinning research environment with clinical laboratory capabilities was implemented and validated in the University of Birmingham within 4 days of the project initiation. The diagnostic capability was centred on an IVD CE-marked RT-PCR kit and designed to provide surge capacity to the nearby Queen Elizabeth Hospital. The service was initially tasked with testing healthcare workers (HCW) using throat swabs, and subsequently the process investigated the utility of using saliva as an alternative sample type.
Results: Between the 8th April 2020 and the 30th April 2020, the laboratory tested a total of 1282 HCW for SARS-CoV-2 RNA in throat swabs. RNA was detected in 54 % of those who reported symptoms compatible with COVID-19, but in only 4% who were asymptomatic.
Conclusion: This capability was established rapidly and utilised a cold-chain free methodology, applicable to a wide range of settings, and which can provide surge capacity and support to clinical laboratories facing increasing pressure during periods of national crisis.

Keywords: Birmingham; COVID-19; Coronavirus; Rapid response; SARS-CoV-2; VIASURE qRT-PCR; West Midlands.
 
Back
Top Bottom